. Adenosine receptor affinities of derivatives in the training set. Table II . Measured and predicted binding affinities and relative efficacies of adenosine derivatives at human A 3 ARs in the training set. ligand for the hydrophobic map. The visualization of the CoMSIA map has been performed using the StDev*Coefficient mapping option contoured by contribution. Favored and disfavored levels fixed at 80% and 20%, respectively, were used for all fields. In the CoMSIA result, the hydrophobic maps are shown in yellow for regions tolerating groups of increased hydrophobic interactions and white for regions unfavoring hydrophobic groups and favoring hydrophilic groups to increase the binding affinity to the A 3 AR.
Supporting results.
Generation of data sets. To achieve a statistically significant 3D-QSAR model, the following conditions are considered generally standard: (1) a minimum range of three log units for compound binding affinity, (2) ~20 compounds (corresponding to ~5 compounds per principal component) for model generation, and (3) even distribution of the biological activities of the compounds. 22 Biological data was derived from several studies [14] [15] [16] [17] [18] [19] [20] [21] that used the same assay conditions and radiolabeled competitive binding agonist, [
125 I]-I-AB-MECA. Thus, the combined data set exhibited a four-log-unit difference between the highest (72: pK i = 9.55) and the lowest (71: pK i = 5.37) binding affinities, with other affinities evenly distributed in that range.
S3
3D-QSAR modeling. The cross-validated q 2 is generally proving to be a much better indicator than r 2 of the reliability of a given predictions. The q 2 is generally somewhat lower, and often much lower than the conventional r 2 value. According to the CoMFA manual, the 95% confidence limit for a q 2 in CoMFA is ~0.3, so statistical significance is unlikely to be the issue. Since one or more unique compounds whose target values are badly predicted are involved in the analysis, cross-validation highlights the potential risks involved in relying on the properties of a single compound, affecting the dramatic decrease of q 2 value. Thus, we calculated q 2 value of each model and increased its value up to >0.5 through omitting an outlier in the residual plot.
To examine the predictability of the training set, preliminary 3D-QSAR studies were carried out for all 91 compounds on the basis of the binding affinity for the A 3 AR subtype with SAMPLS to improve the efficiency and the speed of the 3D-QSAR. A further leaveone-out cross-validation implemented in PLS analysis was performed, in which each compound was systematically excluded from the training data set. To reduce cross-correlated brown noise in the data matrix, region focusing was applied to each model for a selective weighting of the grid points in a region. Only CoMFA (CoMFA-RF1/2) models resulted in an increase of r 2 value; other models did not (data not shown). In concert with q 2 , the predictive r 2 is used to evaluate the overall performance of a model by comparing the accuracy of a series of predictions with the experimentally determined data for a given target property. The power of each model to make predictions for the A 3 AR agonists was validated by using the external test sets. Comparison of the experimentally observed and predicted pKi values at the A 3 AR further confirmed the predictive ability of each model. The residuals between corresponding values S4 of the experimental and predicted binding affinity for each compound were less than one log unit, and all test set compounds followed the regression trend line.
Although traditional CoMFA models exhibited statistical significance comparable to CoMSIA models in the present case, additional hydrophobic and H-bonding fields from CoMSIA give more information on the binding site and receptor activation, which may prove useful for the design of agonists with higher binding affinity. Since the different lattice spacing did not affect the statistical parameters of CoMSIA, one model for the relative efficacy at the A 3 AR was generated with the default value of 2.0 Å lattice spacing.
Since the active conformation of adenosine is unknown, the same alignment of the A 3 AR-bound conformation was used for the generation of CoMSIA-EFF model. Comparison of 3D-QSAR with docking models and activation mechanisms. Brief docking results of hA 3 AR follows. The amine of the N 6 substituent in proximity to N250 (6.55) was H-bonded with the hydroxyl group of S247 (6.52). The 2′-OH group of the ribose ring was involved in H-bonding with the side chain of Q167 (EL2). The 3′-OH group formed a HB with the side chain of H272 S5 (7.43), consistent with our A 3 neoceptor model.
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The 5′-amide NH group formed an intramolecular HB with the 4′-O atom and was close to T94 (3.36), and the 5′-carbonyl oxygen atom formed a HB with S271 (7.41). The aromatic portion of the N 6 -benzyl moiety showed additional π-π stacking interaction with the aromatic ring of F168 (EL2).
Previously, the activation of the human A 3 AR by several adenosine derivatives was studied in intact CHO cells stably expressing this receptor. and a region requiring an acceptor at the 5′-CO group from the CoMSIA-EFF model were located at the side chains of T94 (3.36) and S271 (7.41) in the putative binding site.
In a previous pharmacophore study, A 3 AR-selective agonists required more H-bonding ability than did the pharmacophore of
This pharmacophore study is also consistent with the receptor docking of the agonist, which showed additional H-bonding to the ribose moiety, and with the H-bonding map from the CoMSIA model.
S7
Although there is no global active-state model, local conformational changes have been proposed.
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In agonist-binding domains, compared with antagonist-binding domains, additional interactions were present at the kink site of TM6 and near TM7. The distinct binding sites might have differing effects on the conformational change of activation. Figure 1A for structures of the adenosine derivatives. Affinities were previously reported. The numbers in bold italics indicate outliers in the residual plots from the cross-validation analyses. A B
